ALXO

Alx Oncology Holdings Inc

1.17

Oct 23 • 3:59 PM ET -0.02 (-1.68%)

1.19

Aftermarket • 7:36 PM ET +0.02 (1.71%)

Healthcare Biotechnology USA Micro NASD

Peers: PYXS CGEN MGNX STRO CMPX CTMX IPHA ADAG BCYC CUE

| Held by: VTI IWM VXF IWO VTWO IWC GSSC BUSM FESM VTWG

Scroll to Statements

Index	RUT
Market Cap	161.79M
Enterprise Value	34.60M
Income	-80.89M
Sales	0.00M
Book/sh	0.99
Cash/sh	1.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	43
IPO	Jul 17, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.19
P/C	1.17
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.71
Current Ratio	9.71
Debt/Eq	0.08
LT Debt/Eq	0.07
Option/Short	Yes / Yes

EPS (ttm)	-1.14
EPS next Y	-0.55
EPS next Q	-0.13
EPS this Y	70.56%
EPS next Y	2.21%
EPS next 5Y	34.91%
EPS past 3/5Y	14.52% -8.19%
Sales past 3/5Y	- -
EPS Y/Y TTM	48.20%
Sales Y/Y TTM	-
EPS Q/Q	72.71%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	9.03% -

Insider Own	22.98%
Insider Trans	-0.01%
Inst Own	62.34%
Inst Trans	16.36%
ROA	-63.16%
ROE	-80.65%
ROIC	-55.41%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.91%
SMA50	-26.74%
SMA200	-36.01%
Trades

Shs Outstand	138.22M
Shs Float	106.50M
Short Float	5.33%
Short Ratio	4.91
Short Interest	5.67M
52W High	2.66 -56.02%
52W Low	0.86 35.78%
Volatility	11.44% 12.41%
ATR (14)	0.13
RSI (14)	42.99
Beta	0.61
Rel Volume	0.48
Avg Volume	1.15M
Volume	556,409

Perf Week	10.38%
Perf Month	-13.65%
Perf Quarter	-42.08%
Perf Half Y	-29.94%
Perf YTD	3.54%
Perf Year	-33.14%
Perf 3Y	-83.13%
Perf 5Y	-97.84%
Perf 10Y	-
Recom	1.29
Target Price	4.60
Prev Close	1.19
Price	1.17
Change %	-1.68%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-19-26	Initiated	Wells Fargo	Overweight	$5
Mar-06-26	Resumed	UBS	Buy	$6
Nov-13-25	Initiated	Jefferies	Buy	$4
Mar-06-25	Upgrade	Jefferies	Hold → Buy	$2 → $3
Dec-19-24	Downgrade	Jefferies	Buy → Hold	$12 → $2
Mar-08-24	Downgrade	Stifel	Buy → Hold	$10 → $14
Dec-08-23	Upgrade	Jefferies	Hold → Buy	$8 → $18
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$65 → $25
Sep-30-21	Initiated	Stifel	Buy	$106
May-05-21	Resumed	Credit Suisse	Outperform	$98
Apr-26-21	Resumed	Credit Suisse	Outperform	$98
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy	$100
Aug-11-20	Initiated	Piper Sandler	Overweight	$55
Aug-11-20	Initiated	Jefferies	Buy	$50
Aug-11-20	Initiated	Credit Suisse	Outperform	$53
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight	$64

Show Previous Ratings

Sep-28-26 08:00AM	ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer (GlobeNewswire) +6.11%
Sep-02-26 08:00AM	ALX Oncology to Present at Upcoming Investor Conferences in September (GlobeNewswire) +5.05%
Aug-06-26 08:00AM	ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +9.90%
Jun-30-26 04:40PM	ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules (GlobeNewswire) -5.91%
08:00AM	ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel (GlobeNewswire)
08:00AM	Loading…
Jun-01-26 08:00AM	ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York (GlobeNewswire) -5.26%
May-08-26 08:00AM	ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +11.23%
May-07-26 08:00AM	ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression (GlobeNewswire) -10.53%
Apr-30-26 08:00AM	ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 (GlobeNewswire) +7.59%
Apr-17-26 04:05PM	ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules (GlobeNewswire)
Apr-13-26 08:30AM	ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer (GlobeNewswire)
Mar-10-26 11:38AM	GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma (Zacks)
11:09AM	EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y (Zacks)
Mar-09-26 10:23AM	Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study (Zacks)
Mar-07-26 08:25AM	ALX Oncology initiated with a Buy at UBS (TipRanks)
10:26AM	Loading…
Mar-06-26 10:26AM	LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? (Zacks)
09:57AM	QURE Stock Crashes 32% in a Week: Here's What You Should Know (Zacks)
08:27AM	Mirum Completes Enrollment & Screening in Liver Disease Studies (Zacks)
Mar-05-26 09:18AM	CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data (Zacks)
05:07AM	ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) (Zacks)
Mar-04-26 08:03AM	ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Zacks) +5.80%
Mar-03-26 11:34PM	ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update (MarketBeat)
Feb-27-26 04:04PM	ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... (GuruFocus.com) -10.21%
10:24AM	ALX Oncology Q4 Earnings Call Highlights (MarketBeat)
08:00AM	ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-25-26 09:40AM	Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-19-26 08:33AM	ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 (GlobeNewswire) +12.07%
08:30AM	ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 (GlobeNewswire)
Feb-09-26 09:40AM	Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? (Zacks) +14.15%
Jan-30-26 08:30AM	ALX Oncology Announces Pricing of Underwritten Offering (GlobeNewswire) +10.83%
08:15AM	Loading…
08:15AM	New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer (GlobeNewswire)
Jan-15-26 05:17PM	ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference (MarketBeat) -9.02%
Jan-08-26 11:00AM	ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.08%
08:30AM	ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 (GlobeNewswire)
Dec-07-25 08:00AM	ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting (GlobeNewswire)
Nov-18-25 11:00AM	ALX Oncology to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-08-25 02:05AM	ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... (GuruFocus.com)
Nov-07-25 08:15AM	ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +16.95%
Oct-30-25 08:30AM	ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting (GlobeNewswire)
Oct-23-25 12:30PM	ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference (GlobeNewswire) +8.70%
Oct-14-25 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year? (Zacks) -8.11%
Oct-03-25 09:05AM	ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) +14.14%
Sep-12-25 08:30AM	ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer (GlobeNewswire) -10.17%
Aug-29-25 12:00PM	ALX Oncology to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-19-25 08:00AM	ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors (GlobeNewswire) -8.37%
Aug-13-25 03:13AM	ALX Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com) +7.40%
Aug-12-25 04:05PM	ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 08:00AM	ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire) +12.68%
May-30-25 08:00AM	ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference (GlobeNewswire)
May-20-25 08:00AM	ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event (GlobeNewswire)
May-13-25 08:00AM	ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 (GlobeNewswire) +10.52%
May-08-25 08:30AM	ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-25 08:00AM	ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-28-25 07:51AM	ALX Oncologys CD47-blocker and Keytruda combo fails in two Phase II trials (Clinical Trials Arena)
Apr-25-25 01:10PM	ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma (GlobeNewswire) -9.87%
09:00AM	ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints (GlobeNewswire)
Apr-07-25 08:00AM	ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate (GlobeNewswire)
Mar-20-25 09:55AM	ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Mar-07-25 01:27PM	Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday (Insider Monkey) -19.08%
Mar-06-25 04:01PM	ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +25.96%
Mar-05-25 08:00AM	ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event (GlobeNewswire)
Feb-27-25 08:00AM	ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire)
Feb-18-25 08:00AM	ALX Oncology to Host Virtual R&D Day on March 5, 2025 (GlobeNewswire) +7.27%
Jan-23-25 02:44PM	ALX Oncology Shares Drop 15% Following Positive Phase 2 (GuruFocus.com) -9.44%
08:00AM	ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer (GlobeNewswire)
Jan-22-25 04:01PM	ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules (GlobeNewswire) +9.09%
09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
08:00AM	ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors (GlobeNewswire)
Jan-21-25 05:00PM	ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI (GlobeNewswire) -5.17%
Jan-07-25 09:40AM	Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 08:57AM	Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' (Investing.com) -19.57%
Dec-18-24 08:00AM	ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-12-24 08:00AM	ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 (GlobeNewswire) -5.96%
Dec-10-24 09:00AM	ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer (GlobeNewswire) -8.14%
Nov-26-24 08:00AM	ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-21-24 09:35AM	ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +6.61%
Nov-14-24 08:00AM	ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-07-24 04:00PM	ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-24 08:00AM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire)
Nov-01-24 05:30PM	ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 (GlobeNewswire)
Oct-10-24 07:04PM	Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc (GuruFocus.com) -11.11% +6.94%
Sep-09-24 08:00AM	ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +9.95%
Sep-04-24 08:00AM	ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi (GlobeNewswire)
Aug-08-24 04:05PM	ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-24 04:01PM	ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors (GlobeNewswire) -6.55%
Aug-01-24 09:05AM	Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients (Benzinga) -41.67%
06:52AM	ALX Oncologys evorpacept shows potential in Phase II gastric cancer trial (Clinical Trials Arena)
Jul-31-24 04:01PM	ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer (GlobeNewswire) -11.93%
05:30AM	ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Jun-17-24 11:00AM	Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO) (GuruFocus.com) -8.32%
Jun-03-24 09:35AM	Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround (Zacks) -15.71%
Jun-02-24 10:00AM	ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer (GlobeNewswire)
May-29-24 09:00AM	ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire) -10.91%
May-16-24 02:54AM	Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares (GuruFocus.com)
May-14-24 09:55AM	Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet (Zacks)
May-10-24 02:21PM	ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ... (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Aug 17 '26	Sale	1.93	2,230	4,304	294,379	Aug 18 05:51 PM
Wong Shelly	SVP, FINANCE AND CAO	Aug 17 '26	Sale	1.93	573	1,106	87,828	Aug 18 05:50 PM
Wong Shelly	SVP, FINANCE AND CAO	Jul 01 '26	Sale	2.04	1,404	2,864	88,401	Jul 06 04:30 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Mar 19 '26	Sale	2.17	12,311	26,715	293,609	Mar 23 04:05 PM
Pinto Shelly	SVP, FINANCE AND CAO	Mar 19 '26	Sale	2.17	903	1,960	86,805	Mar 23 04:05 PM
Pinto Shelly	SVP, FINANCE AND CAO	Feb 18 '26	Sale	2.27	565	1,283	87,708	Feb 20 04:01 PM
GOODMAN COREY S	Director	Feb 02 '26	Buy	1.57	3,184,713	4,999,999	8,453,038	Feb 04 04:15 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jan 06 '26	Sale	1.11	3,925	4,357	88,273	Jan 07 04:30 PM

ALX Oncology Holdings, Inc. is a clinical-stage biotechnology company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

CEO & DirectorMr. Jason W. Lettmann

Chief Financial OfficerMr. Harish Shantharam C.F.A.

Senior VP of Finance & Chief Accounting OfficerMs. Shelly Wong C.P.A.

Chief Medical OfficerDr. Barbara J. Klencke M.D.

Chief Development & Operating OfficerMr. Jeff E. Knight M.P.H.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALXO

Alx Oncology Holdings Inc

Upgrade your Finviz experience